180-wide.par.99002.image.0.0.1
Study post-translational modifications in a physiologically relevant cellular context.  With this assay format you can:

  • Screen quickly with a simple and homogenous high-throughput screening (HTS) – amenable assay format
  • Interrogate the effects of your compounds on specific signaling events within a pathway
  • Analyze multiple post-translational modifications using physiological pathway kinetics

To view the available LanthaScreen™ cellular assays, plus extensive validation data and protocols specific to each post-translational modification available, please see our LanthaScreen™ cellular assay validation table.

Request Assay Information        Use Assay Maker™

Assay Principle

The cellular response to environmental cues is mediated through a complex network of signal transduction pathways.  Alteration or disruption of components within these pathways often contributes to various diseases, including cancer and metabolic and inflammatory disorders.  The diversity of validated drug targets in these signal transduction cascades provides both challenges and opportunities in drug discovery.  Intermediate signaling events, such as phosphorylation and ubiquitination, are bona fide targets for assay development.  Until now, there have been a limited number of HTS-compatible methods available to interrogate, in a cell-based format, the regulated activity of enzymes responsible for posttranslational modifications.

Combining the simplicity of biochemical assays with the intricacy of cellular systems, Invitrogen has developed time-resolved fluorescence resonance energy transfer (TR-FRET)-based assays to monitor protein modification within the native cell signaling environment.  By expressing the substrate of interest as a fusion with green fluorescent protein (GFP), modification-specific antibodies labeled with the TR-FRET donor partner terbium (Tb) can be used to quantitatively monitor these modifications following cell lysis (Figure 1).

Figure 1. Schematic of LanthaScreen™ cellular assay.
The principle and methods for this assay format are simple.  1) Phosphorylation of the kinase substrate expressed as a GFP-fusion protein is either stimulated with an agonist to activate the pathway or treated with an inhibitor to interrupt the signaling event.  No protein modification occurs in unstimulated cells.  2) Cells are lysed in a buffer that contains a Tb-labeled phosphorylation site-specific antibody.  The detection of the protein modification event is measured on a TR-FRET-compatible plate reader.  Little or no TR-FRET is observed with unstimulated or inhibited cells whereas stimulated cell samples display high TR-FRET.
Optimize workflows for HTS applications

Compared to classical and established methods for phosphoprotein analysis, such as western blotting and ELISA, the workflow for a LanthaScreen™ cellular assay is quick, designed for HTS screening in a 384-well plate, and highly amenable to automation (Figure 2).


Figure 2—Comparison of LanthaScreen™ cellular assay and phosphoELISA™ workflow. The LanthaScreen™ cellular assay platform offers a high-throughput alternative for compound screening and profiling.  In contrast to the traditional ELISA-based approach for phospho-protein analysis, this assay format requires minimal hands-on time and can be run in as few as 2−3 hours as opposed to the typical 6- to 8-hour time commitment with classical phosphoELISA™ assays. (Phosphorylation site-specific antibodies; PSSA).
This assay format has no wash steps, and the assays can be run following an “addition only” protocol, requiring little hands-on time and eliminating the need for extra manual touches and liquid transfer steps. Moreover, the data obtained in the LanthaScreen™ cellular assay format are equivalent to those generated using a phosphoELISA™ (Figure 3).
Figure 3—Equivalent experimental data generated using a LanthaScreen™ cellular assay and a phosphoELISA™.  HEK293E cells were treated with different concentrations of the dual PI3K/mTOR inhibitor PI-103 and subsequently analyzed using the PRAS40 [pT246] phosphoELISA™ kit from Invitrogen.  The inhibitor data are overlaid with the results from the LanthaScreen™ PRAS40 [T246] HEK293E assay, with nearly identical IC50 values (~200 nM).  Together, these data indicate that the LanthaScreen™ cellular assay format is a suitable surrogate for established methods for phosphoprotein analysis.

Ordering Information

Sku Name Size Price Qty
K1615 LanthaScreen® Akt HEK 293E Cell Line 1 vial USD 9,880.00
K1679 LanthaScreen® ATF2 (19-106) A549 Cell Line 1 vial USD 9,880.00
K1798 LanthaScreen® ERK2 A375 Cell Line 1 vial USD 9,880.00
K1587 LanthaScreen® ERK2 U2OS Cell Line 1 vial USD 9,880.00
K1681 LanthaScreen® IkB alpha GripTite™ Cell Line 1 vial USD 9,880.00
K1680 LanthaScreen® c-Jun (1-79) HeLa Cell Line 1 vial USD 9,880.00
K1593 LanthaScreen® PDCD4 HEK 293E Cell Line 1 vial USD 9,880.00
K1528 LanthaScreen® PRAS40 293E Cell Line 1 vial USD 9,880.00
K1469 LanthaScreen® STAT1 U2OS Cell Line 1 vial USD 9,880.00
K1488 LanthaScreen® STAT3 GripTite™ Cell Line 1 vial USD 9,880.00
K1598 LanthaScreen® STAT5 TF-1 Cell Line 1 vial USD 9,880.00
K1588 LanthaScreen® STAT5 (JAK2 V617F) U2OS Cell Line 1 vial USD 9,880.00
K1834 LanthaScreen® IGF-1R GripTite™ Cell Line 1 vial USD 9,880.00